$1.1 billion support for COVID-19 medical research and vaccine development

Prime Minister Justin Trudeau held media briefing on April 23, 2020. / Global Korean Post

More than $1 billion support for COVID-19 medical research and vaccine development

 

April. 24, 2020

Global Korean Post

 

New information on COVID-19 emerges every day. Researchers and scientists in Canada and around the world are working hard to better understand the virus, and its impacts on people and communities.

The Prime Minister, Justin Trudeau, on April 23, announced more than $1 billion in support of a national medical research strategy to fight COVID-19 that includes vaccine development, the production of treatments, and tracking of the virus. This new funding builds on the $275 million investment for coronavirus research and medical countermeasures announced in March.

The Government of Canada will invest in new medical countermeasures to better understand COVID-19, and develop the infrastructure needed to fight the virus here in Canada. This includes:

  • The establishment of the COVID-19 Immunity Task Force that will operate under the direction of a leadership group, which will include Dr. David Naylor, Dr. Catherine Hankins, Dr. Tim Evans, Dr. Theresa Tam, and Dr. Mona Nemer. The task force will establish priorities and oversee the coordination of a series of country-wide blood test surveys that will tell us how widely the virus has spread in Canada and provide reliable estimates of potential immunity and vulnerabilities in Canadian populations.
  • $40 million for the Canadian COVID-19 Genomics Network (CanCOGeN), led by Genome Canada, to coordinate a COVID-19 viral and host genome sequencing effort across Canada. This research will help track the virus, its different strains, and how it makes people sick in different ways, providing valuable information to public health authorities and decision-makers as they put in place measures to control the pandemic. The results of this work will be available to researchers globally to support additional research, including Canadian vaccine development efforts.
  • $23 million for the Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) to accelerate development of a vaccine against COVID-19. This funding will support pre-clinical testing and clinical trials of a potential COVID-19 vaccine, essential steps to ensuring that vaccines are effective and safe for human use.
  • $29 million for the National Research Council of Canada to begin the second phase of critical upgrades to its Human Health Therapeutics facility in Montréal. Building on ongoing work to ready the facility for the production of vaccines for clinical trials, this funding will support operations to maintain the facility, as well as provide infrastructure to prepare vials for individual doses as soon as a vaccine becomes available.
  • $600 million, through the Strategic Innovation Fund, over two years to support COVID-19 vaccine and therapy clinical trials led by the private sector, and Canadian biomanufacturing opportunities.
  • $10 million for a Canadian data monitoring initiative so we can coordinate and share pandemic-related data across the country to enhance Canada’s response to COVID-19.
  • $10.3 million over two years, and $5 million ongoing, to support the Canadian Immunization Research Network in conducting vaccine-related research and clinical trials, and to enhance Canada’s capacity to monitor vaccine safety and effectiveness.
  • $114.9 million through the Canadian Institutes of Health Research for research projects that will accelerate the development, testing, and implementation of medical and social countermeasures to mitigate the rapid spread of COVID-19, as well as its social and health impacts.

Separately, the Government of Canada is providing over $675,000 through the Stem Cell Network to support two new research projects and one clinical trial. The clinical trial will evaluate the safety of a potential cell therapy to reduce the impacts and severity of acute respiratory distress associated with COVID-19, and the two projects will generate critical information about how cells in the airway and brain are affected by the virus.

 

--